• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

药物在固体脂质微粒(SLM)中的分布——分析与解读方法

Distribution of Drug Substances in Solid Lipid Microparticles (SLM)-Methods of Analysis and Interpretation.

作者信息

Wolska Eliza, Brach Marta

机构信息

Department of Pharmaceutical Technology, Medical University of Gdansk, Hallera 107, 80-416 Gdansk, Poland.

Student Chapter of the International Society of Pharmaceutical Engineering (ISPE), Hallera 107, 80-416 Gdansk, Poland.

出版信息

Pharmaceutics. 2022 Jan 31;14(2):335. doi: 10.3390/pharmaceutics14020335.

DOI:10.3390/pharmaceutics14020335
PMID:35214067
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8879661/
Abstract

The incorporation of drug substances into the matrix of solid lipid microparticles (SLM) is critical to providing effects such as prolonged release, taste masking, and protection of the labile API. Currently, a commonly used method of characterizing multi-compartment lipid systems, such as SLM, is to determine entrapment efficiency (EE) and drug loading (DL) parameters, but this is not sufficient for understanding the localization of API either in the core or on the surface of the microspheres. The main objective of the research was to study the distribution of API in an aqueous dispersion of SLM in order to distinguish between the API incorporated in the lipid matrix and localized in the superficial region (interphase) and to refer the obtained results to the EE and DL parameters. SLM dispersions (10-30% of the lipid) with four model drug substances, i.e., cyclosporine, clotrimazole, diclofenac sodium and hydrocortisone, were prepared and investigated. In the first stage, the experiments were designed to optimize the method of extracting the API fraction localized on the SLM surface by shaking the dispersions with methanol. The fraction dissolved in the aqueous phase was obtained by ultrafiltration of SLM dispersions. Total drug content and the concentration in the separated phases were determined by the HPLC method. The obtained results were compared with the EE and DL parameters. Selected SLM dispersions were tested both before and after thermal sterilization. Short-term shaking of SLM dispersion with methanol does not damage the lipid matrix and allows the API fraction localized on the SLM surface to be extracted, the result of which was the determination of API distribution between lipid matrix, interphase and aqueous phase. It was found that the majority of API represented by EE value was localized on the surface of SLM. Only for cyclosporine was the incorporation of drug molecules in the lipid core very effective (up to 48%), while for other drug substances only 1-21% was found in the lipid core of SLM. A clear influence of the sterilization process on the distribution of API within the microparticles was found. The presented studies showed that the characterization of multi-compartment SLM dispersions solely on the basis of EE and DL values, is insufficient. The proposed new distribution test method enables the localization of API to be demonstrated within the microspheres, with the quantitative characteristics of the drug fraction incorporated in the lipid matrix and the fraction associated with the surface of the lipid matrix. The proposed new method allows the influence of the sterilization process on the changes in the API distribution within the lipospheres to be evaluated. Such characteristics provide new opportunities for the development and use of this dosage form as a carrier providing prolonged release and other aforementioned advantages.

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c1e/8879661/b12c0222293e/pharmaceutics-14-00335-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c1e/8879661/3593d07072ea/pharmaceutics-14-00335-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c1e/8879661/09a8f4309dc3/pharmaceutics-14-00335-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c1e/8879661/04ebe6e2a4f2/pharmaceutics-14-00335-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c1e/8879661/b12c0222293e/pharmaceutics-14-00335-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c1e/8879661/3593d07072ea/pharmaceutics-14-00335-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c1e/8879661/09a8f4309dc3/pharmaceutics-14-00335-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c1e/8879661/04ebe6e2a4f2/pharmaceutics-14-00335-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c1e/8879661/b12c0222293e/pharmaceutics-14-00335-g004.jpg
摘要

将药物掺入固体脂质微粒(SLM)的基质中对于实现诸如延长释放、掩味以及保护不稳定的活性药物成分(API)等效果至关重要。目前,表征多室脂质系统(如SLM)的常用方法是测定包封率(EE)和载药量(DL)参数,但这不足以了解API在微球核心或表面的定位情况。该研究的主要目的是研究API在SLM水分散体中的分布,以区分掺入脂质基质和位于表面区域(界面)的API,并将所得结果与EE和DL参数相关联。制备并研究了含有四种模型药物(即环孢素、克霉唑、双氯芬酸钠和氢化可的松)的SLM分散体(脂质含量为10 - 30%)。在第一阶段,通过用甲醇振荡分散体来优化提取位于SLM表面的API部分的方法。通过对SLM分散体进行超滤获得溶解在水相中的部分。通过高效液相色谱法测定总药物含量和分离相中药物的浓度。将所得结果与EE和DL参数进行比较。对选定的SLM分散体在热灭菌前后均进行了测试。用甲醇对SLM分散体进行短期振荡不会破坏脂质基质,并能提取位于SLM表面的API部分,其结果是确定了API在脂质基质、界面和水相之间的分布。结果发现,以EE值表示的大部分API位于SLM表面。仅环孢素的药物分子在脂质核心中的掺入非常有效(高达48%),而对于其他药物,在SLM的脂质核心中仅发现1 - 21%。发现灭菌过程对API在微粒内的分布有明显影响。所呈现的研究表明,仅基于EE和DL值对多室SLM分散体进行表征是不够的。所提出的新的分布测试方法能够证明API在微球内的定位情况,以及掺入脂质基质中的药物部分和与脂质基质表面相关的药物部分的定量特征。所提出的新方法能够评估灭菌过程对脂质球内API分布变化的影响。这些特性为开发和使用这种剂型作为提供延长释放及其他上述优势的载体提供了新的机会。

相似文献

1
Distribution of Drug Substances in Solid Lipid Microparticles (SLM)-Methods of Analysis and Interpretation.药物在固体脂质微粒(SLM)中的分布——分析与解读方法
Pharmaceutics. 2022 Jan 31;14(2):335. doi: 10.3390/pharmaceutics14020335.
2
Analytical Techniques for the Assessment of Drug-Lipid Interactions and the Active Substance Distribution in Liquid Dispersions of Solid Lipid Microparticles (SLM) Produced de novo and Reconstituted from Spray-Dried Powders.用于评估药物-脂质相互作用以及在新制备的和由喷雾干燥粉末重构的固体脂质微粒(SLM)液体分散体中活性物质分布的分析技术。
Pharmaceutics. 2020 Jul 15;12(7):664. doi: 10.3390/pharmaceutics12070664.
3
Ocular irritation and cyclosporine A distribution in the eye tissues after administration of Solid Lipid Microparticles in the rabbit model.固体脂质微球给药后兔眼组织中环孢素 A 的分布及眼刺激性。
Eur J Pharm Sci. 2018 Aug 30;121:95-105. doi: 10.1016/j.ejps.2018.05.015. Epub 2018 May 16.
4
Technology of stable, prolonged-release eye-drops containing Cyclosporine A, distributed between lipid matrix and surface of the solid lipid microspheres (SLM).载有环孢素 A 的稳定、长效滴眼剂的技术,分布在脂质基质和固体脂质微球(SLM)的表面之间。
Int J Pharm. 2013 Jan 30;441(1-2):449-57. doi: 10.1016/j.ijpharm.2012.11.009. Epub 2012 Nov 16.
5
Comparison of the In Vitro Drug Release Methods for the Selection of Test Conditions to Characterize Solid Lipid Microparticles.用于选择表征固体脂质微粒测试条件的体外药物释放方法的比较
Pharmaceutics. 2023 Feb 3;15(2):511. doi: 10.3390/pharmaceutics15020511.
6
Testosterone solid lipid microparticles for transdermal drug delivery. Formulation and physicochemical characterization.用于透皮给药的睾酮固体脂质微粒。制剂及理化特性
J Microencapsul. 2007 Aug;24(5):457-75. doi: 10.1080/02652040701368865.
7
Drug Release from Lipid Microparticles-Insights into Drug Incorporation and the Influence of Physiological Factors.脂质微粒中的药物释放——药物包封及生理因素影响的深入见解
Pharmaceutics. 2024 Apr 15;16(4):545. doi: 10.3390/pharmaceutics16040545.
8
The effect of a lipid composition and a surfactant on the characteristics of the solid lipid microspheres and nanospheres (SLM and SLN).脂质组合物和表面活性剂对固体脂质微球和纳米球(SLM和SLN)特性的影响。
Eur J Pharm Biopharm. 2017 Jan;110:24-30. doi: 10.1016/j.ejpb.2016.10.023. Epub 2016 Nov 1.
9
Solid lipid microparticles (SLM) containing juniper oil as anti-acne topical carriers: preliminary studies.含有杜松子油作为抗痤疮局部用载体的固体脂质微粒(SLM):初步研究。
Pharm Dev Technol. 2005;10(4):479-87. doi: 10.1080/10837450500299727.
10
Rheological and solid-state NMR assessments of copovidone/clotrimazole model solid dispersions.共聚维酮/克霉唑模型固体分散体的流变学和固态核磁共振评估
Int J Pharm. 2016 Mar 16;500(1-2):20-31. doi: 10.1016/j.ijpharm.2016.01.026. Epub 2016 Jan 15.

引用本文的文献

1
Cyclosporine Dissolution Test from a Lipid Dosage Form: Next Step Towards the Establishment of Release Method for Solid Lipid Microparticles.脂质剂型中环孢素的溶出度试验:迈向建立固体脂质微粒释放方法的下一步。
Pharmaceutics. 2025 Aug 8;17(8):1030. doi: 10.3390/pharmaceutics17081030.
2
Innovative nanostructured lipid-particles of apocynin and clove oil tagged with Chitin oligosaccharide for amelioration of tacrolimus-induced nephrotoxicity.载有壳寡糖标记的阿朴吗啡和丁香油的新型纳米结构脂质颗粒用于改善他克莫司诱导的肾毒性。
Sci Rep. 2025 Aug 8;15(1):29011. doi: 10.1038/s41598-025-13978-1.
3
Drug Release from Lipid Microparticles-Insights into Drug Incorporation and the Influence of Physiological Factors.

本文引用的文献

1
Lidocaine-Loaded Solid Lipid Microparticles (SLMPs) Produced from Gas-Saturated Solutions for Wound Applications.由气体饱和溶液制备的用于伤口治疗的载利多卡因固体脂质微粒(SLMPs)
Pharmaceutics. 2020 Sep 12;12(9):870. doi: 10.3390/pharmaceutics12090870.
2
Analytical Techniques for the Assessment of Drug-Lipid Interactions and the Active Substance Distribution in Liquid Dispersions of Solid Lipid Microparticles (SLM) Produced de novo and Reconstituted from Spray-Dried Powders.用于评估药物-脂质相互作用以及在新制备的和由喷雾干燥粉末重构的固体脂质微粒(SLM)液体分散体中活性物质分布的分析技术。
Pharmaceutics. 2020 Jul 15;12(7):664. doi: 10.3390/pharmaceutics12070664.
3
脂质微粒中的药物释放——药物包封及生理因素影响的深入见解
Pharmaceutics. 2024 Apr 15;16(4):545. doi: 10.3390/pharmaceutics16040545.
4
TPGS-mediated Transethosomes Enhance Transdermal Administration of Curcumin Effects on Deformability and Stability.TPGS介导的转质体增强姜黄素的透皮给药:对变形性和稳定性的影响
Curr Drug Deliv. 2025;22(4):479-491. doi: 10.2174/0115672018279577231208055415.
5
Comparison of the In Vitro Drug Release Methods for the Selection of Test Conditions to Characterize Solid Lipid Microparticles.用于选择表征固体脂质微粒测试条件的体外药物释放方法的比较
Pharmaceutics. 2023 Feb 3;15(2):511. doi: 10.3390/pharmaceutics15020511.
Evaluation of solubility and dissolution of lamotrigine using lipid based microparticulate carriers: An in-vitro analysis.
使用脂质基微粒载体评估拉莫三嗪的溶解度和溶出度:体外分析
Pak J Pharm Sci. 2020 Jan;33(1(Supplementary)):299-306.
4
Solid lipid nanoparticles: a review on recent perspectives and patents.固体脂质纳米粒:近期研究进展与专利的综述。
Expert Opin Ther Pat. 2020 Mar;30(3):179-194. doi: 10.1080/13543776.2020.1720649. Epub 2020 Jan 31.
5
Nanoparticles fabricated from bulk solid lipids: Preparation, properties, and potential food applications.由块状固体脂质制成的纳米粒子:制备、性质和潜在的食品应用。
Adv Colloid Interface Sci. 2019 Nov;273:102033. doi: 10.1016/j.cis.2019.102033. Epub 2019 Aug 31.
6
Solid lipid nanoparticles and nanostructured lipid carriers: A review emphasizing on particle structure and drug release.固体脂质纳米粒和纳米结构脂质载体:着重于粒子结构和药物释放的综述。
Eur J Pharm Biopharm. 2018 Dec;133:285-308. doi: 10.1016/j.ejpb.2018.10.017. Epub 2018 Oct 27.
7
Ocular irritation and cyclosporine A distribution in the eye tissues after administration of Solid Lipid Microparticles in the rabbit model.固体脂质微球给药后兔眼组织中环孢素 A 的分布及眼刺激性。
Eur J Pharm Sci. 2018 Aug 30;121:95-105. doi: 10.1016/j.ejps.2018.05.015. Epub 2018 May 16.
8
Characterization Methods for Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC).固体脂质纳米粒(SLN)和纳米结构脂质载体(NLC)的表征方法
Curr Pharm Des. 2017 Nov 14. doi: 10.2174/1381612823666171115105721.
9
The impact of particle preparation methods and polymorphic stability of lipid excipients on protein distribution in microparticles.颗粒制备方法和脂质辅料的多晶型稳定性对微粒中蛋白质分布的影响。
Drug Dev Ind Pharm. 2017 Dec;43(12):2032-2042. doi: 10.1080/03639045.2017.1361967. Epub 2017 Aug 11.
10
Cyclosporine A delivery to the eye: A comprehensive review of academic and industrial efforts.环孢素A眼部给药:学术与产业研究的全面综述
Eur J Pharm Biopharm. 2017 Aug;117:14-28. doi: 10.1016/j.ejpb.2017.03.006. Epub 2017 Mar 14.